General Electric has moved to sell its growing biopharma manufacturing business to Danaher in a $21.4 billion deal, as the conglomerate looks to slim down its operations and pay off its lingering debt.
The trade represents an early milestone in GE’s strategy to refocus its various businesses under its newly installed chairman and CEO, Larry Culp, who took the reins last September—and who once served as Danaher’s CEO himself, from 2001 to 2014.
Danaher plans to carve out GE’s biopharma activities and operate them as a standalone business. This includes instruments and services used in biologics R&D and manufacturing, as well as the development of cell and gene therapies, such as modular therapy production lines, chromatography hardware, cell culture media and software programs.
The unit is expected to bring in about $3.2 billion in 2019 sales, with about three-quarters considered recurring revenue partly linked to its consumable products and single-use technologies. The two companies aim to close the deal in the fourth quarter of this year, with Danaher hoping to see about $100 million in cost synergies over the three years to follow.
The acquisition would also provide an “excellent complement” to Danaher’s current biologics manufacturing work, with an opportunity to provide end-to-end bioprocessing solutions to GE Biopharma’s customers, President and CEO Thomas Joyce said in a statement.
“We expect GE Biopharma to advance our growth and innovation strategy in an important and highly attractive life science market,” Joyce said, with the new purchase slotting in next to the company’s Pall, Beckman Coulter, Leica Microsystems and Sciex businesses.
GE, meanwhile, will hold on to the rest of its $17 billion healthcare business—for the time being.
“We are retaining full flexibility for growth and strategic optionality with one of the world’s leading healthcare companies, and we are pleased that our BioPharma colleagues will join a strong, established team at Danaher,” Culp said in a statement. “A more focused portfolio is the right structure for GE, and we have many options for maximizing shareholder value along the way.”
Pharmaceutical diagnostics, for example—including radiology contrast media and molecular imaging consumables—will stay within the company, linked to GE Healthcare’s stanchion medical imaging business.
GE had once planned to spin off its healthcare unit as a whole, into a 52,000-employee company with a potential enterprise value topping $70 billion. Last December it was reported that GE had filed a confidential IPO set for early 2019—but that’s now unlikely to happen following the new deal with Danaher, Culp told CNBC.
GE’s shares rose about 10% in premarket trading on the news to over $11, while Danaher’s grew at least 7.5% to over $121.
By Conor Hale
Source: Fierce Biotech
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.